Keppra Information
What's inside Keppra
Keppra Active Ingredients: levetiracetam, details.| Keppra Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Keppra 500 mg | tablet | oral | 1.0 each | OTC |
| Keppra 750 mg | tablet | oral | 1.0 each | OTC |
| Keppra 250 mg | tablet | oral | 1.0 each | OTC |
| Keppra 1000 mg | tablet | oral | 1.0 each | OTC |
| Keppra 100 mg/mL | solution | oral | 1.0 milliliter(s) | OTC |
| Keppra 100 mg/mL | solution | intravenous | 1.0 milliliter(s) | OTC |
Recent Keppra Side Effects
Posted by bichon1 4 months ago
I am taking 500 mg. tablets (3 twice a day) and not really having any reportable side effects. My neurologist has recently a...
Posted by smiffboove99 about 1 year ago
My neurologist started me on Keppra about 10 months ago after I began having an increase in partial seizure episodes. I can h...
Posted by samantha7 about 1 year ago
I have been on Keppra for over a year now due to high risk of seizures and just a general case of epilepsy and since i've bee...
Keppra in the News
UCB says net profit fell 59 percent - International Herald Tribune
Sales of UCB's anti-epileptic drug Keppra, the company's main product, rose 35 percent to €1.0 billion (US$1.5 billion), UCB said in a statement. ...
Fri Feb 29 05:39:07 -0500 2008
UCB: Full Year 2007 Financial Results - PR-USA.net (press release)
Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing ...
Mon Mar 03 17:43:41 -0500 2008
UPDATE 1-UCB 2007 net hit by Schwarz buy, repeats outlook - Reuters
Growth was predominantly from epilepsy drug Keppra, with sales of more than 1 billion euros, while costs attached to the Schwarz merger and marketing ...
Fri Feb 29 01:40:11 -0500 2008
Keppra Chemical Information
levetiracetam - A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
Keppra RSS Feed
